Avillion   Report issue

For profit Phase 2 Phase 3
Founded: London United Kingdom (2012)

Organization Overview

First Clinical Trial
2014
NCT02130557
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Avillion LLP | Bond Avillion 2 Development LP